Noteworthy, compelling data from previous experimental models have shown that butyrate can significantly attenuate NASH through thickening of the gut chemical barrier, modulation of gut microbiota, activation of the GLP-1R expression, inhibitory effects of proinflamation, and oxidative damage signaling pathway (Jin et al., 2015; Zhou et al., 2017; Ye et al., 2018; Zhou et al., 2018). Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.